Profound weight loss associated with reboxetine use in a 44‐year‐old woman

Lu, Taoying; Kupa, Ann; Easterbrook, G.; Mangoni, Arduino A.

doi:10.1111/j.1365-2125.2005.02407.x

Cited by 11 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there is no information about the exact sequence of events in these reports. 5 Similar to our case, Lu et al [5] report a case of significant weight loss experienced by a 44-year-old woman treated with reboxetine. However their reported case had a number of comorbid medical disorders including chronic hepatitis C infection, rheumatoid arthritis, gastroesophageal reflux disease, and hypertension.…”

Section: Discussionsupporting

confidence: 62%

“…The studies testing the effects of reboxetine on body weight have demonstrated that reboxetine reduces body weight [4]. However there are only a few cases in the literature of reboxetine use in adults resulting in profound weight loss [5]. We present an unusual case report of a patient who experienced a marked weight loss with reboxetine treatment, regained weight after its withdrawal and experienced marked weight loss after re-challenge with reboxetine.…”

Section: Introductionmentioning

confidence: 89%

See 1 more Smart Citation

A Case of Profound Weight Loss Secondary to use of Reboxetine

Doksat¹

2014

J Child Adolesc Behav

View full text Add to dashboard Cite

Reboxetine is a selective norepinephrine re-uptake inhibitor used in the treatment of depression. The studies testing the effects of reboxetine on body weight have demonstrated that reboxetine reduces body weight and reboxetine found to be superior to placebo in reducing antipsychotic-induced weight gain. To date there are only a few cases in the literature of reboxetine use in adults resulting in profound weight loss. We present an unusual case report of a patient who experienced a marked weight loss with reboxetine treatment, regained weight after its withdrawal and experienced marked weight loss after re-challenge with reboxetine.

show abstract

Section: Discussionsupporting

confidence: 62%

Section: Introductionmentioning

confidence: 89%

A Case of Profound Weight Loss Secondary to use of Reboxetine

Doksat¹

2014

J Child Adolesc Behav

View full text Add to dashboard Cite

show abstract

“…Reboxetine is a selective norepinephrine reuptake inhibitor (NRI) and is a new psychotropic drug broadly used as an antidepressant and antianxiety agent, which has been reported to have effects on weight loss [ 21 ]. Lu et al reported a case significant weight loss treated with reboxetine at 12 mg daily for a total duration of 11 months [ 22 ]. Through stimulation of NE activity by the selective NRI, reboxetine is considered to diminish olanzapine induced weight gain [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

“…That means patients could get obese in spite of taking reboxetine for weight reduction, which reflects that the medication seems ineffective treatment option for weight reduction of patients prescribed atypical antipsychotics [ 23 ]. Reboxetine is known as a mediator of enhancing cognitive dysfunction in schizophrenia patients; long-term studies using higher dosages are needed to determine the role of reboxetine as cognitive enhancers in patients with schizophrenia and other disorders associated with cognitive impairments [ 22 , 23 ]. Conversely, in this review, the reboxetine group did not show statistical difference of psychiatric symptom improvement compared to the placebo group.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Adjunctive Treatments Added to Olanzapine or Clozapine for Weight Control in Patients with Schizophrenia: A Systematic Review and Meta‐Analysis

Choi

2015

The Scientific World Journal

View full text Add to dashboard Cite

Objectives. This study was conducted to review systematically adjunctive treatments for weight reduction in patients with schizophrenia and compare efficacies of clinical trials through meta-analysis, so as to provide effective clinical guideline regarding weight control for patients taking atypical antipsychotics. Methods. Candidate clinical trials were identified through searching the Cochrane Central Register of Controlled Trials, PubMed, and PsycINFO. Fourteen randomized clinical trials were included for systematic review and meta-analysis from 132 potential trials. The Comprehensive Meta-Analysis version 2 was used for meta-analysis. Results. Difference in means and significances from meta-analyses regarding weight control by adjunctive treatments showed that topiramate, aripiprazole, or sibutramine was more effective than metformin or reboxetine. Psychiatric evaluations did not show statistically significant changes between treatment groups and placebo groups except topiramate adjunctive treatments. Adverse effects regarding adjunctive therapies were tolerable and showed statistically no significances compared to control groups. Conclusion. Though having several reports related to exacerbation of psychiatric symptoms, topiramate and aripiprazole are more efficacious than other medications in regard to weight reduction and less burden of critical adverse effects as well as being beneficial for clinical improvement.

show abstract

“…Reboxetine has not been evaluated in obese patients. However, a case of significant weight loss in normal weight woman treated with reboxetine was described 9 …”

Section: Centrally Acting Drugs That Affect Serotonin and Norepinephrmentioning

confidence: 99%

Serotonin and Norepinephrine Reuptake Inhibition and Eating Behavior

Hainer

Kabrnová

Aldhoon

et al. 2006

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Brain neurotransmitters, serotonin and norepinephrine, play an important role in the central nervous control of energy balance and are involved in symptomatology related to both obesity and depression. Therefore both serotonin and norepinephrine neural pathways have been paid a special attention as targets for the antiobesity drugs, antidepressants, and drugs used in the treatment of eating disorders. Selective serotonin reuptake inhibitors (SSRI) have been used in the treatment of depression and eating disorders but have failed to achieve sustained weight loss in the treatment of obesity. Sibutramine, a serotonin and norepinephrine reuptake inhibitor, which induces satiety and prevents decline in metabolic rate associated with a hypocaloric diet, is currently the sole centrally acting drug indicated for the long-term treatment of obesity. Depression, dietary disinhibition (evaluated by the Eating Inventory [EI]), and stress are associated with the accumulation of abdominal fat and the development of metabolic syndrome and related diseases. Subjects with abdominal obesity demonstrate neuroendocrine abnormalities which result in disturbances in hypothalamo-pituitary-adrenal (HPA) function. Treatment with SSRI might interrupt the vicious circle which leads to endocrine abnormalities and the accumulation of abdominal fat. Obesity treatment with sibutramine results, not only in significant weight loss, but also in reduction of abdominal fat and in the improvement of health risks associated with metabolic syndrome (lipid profile, blood glucose, insulin, HbA1c, and uric acid), as well as in the decline in disinhibition score of the EI. In a 1-year sibutramine trial, only a decrease in the disinhibition score remained a significant correlate of weight loss among the psychobehavioral and nutritional factors which were taken into account.

show abstract

Profound weight loss associated with reboxetine use in a 44‐year‐old woman

Cited by 11 publications

References 8 publications

A Case of Profound Weight Loss Secondary to use of Reboxetine

A Case of Profound Weight Loss Secondary to use of Reboxetine

Efficacy of Adjunctive Treatments Added to Olanzapine or Clozapine for Weight Control in Patients with Schizophrenia: A Systematic Review and Meta‐Analysis

Serotonin and Norepinephrine Reuptake Inhibition and Eating Behavior

Contact Info

Product

Resources

About